{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:48:28Z","timestamp":1791478108916,"version":"4.3.4"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T00:00:00Z","timestamp":1581552000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T00:00:00Z","timestamp":1581552000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Neurol"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s11940-020-0616-8","type":"journal-article","created":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T03:02:35Z","timestamp":1581562955000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Newer Immunotherapies for the Treatment of Acute Neuromuscular Disease in the Critical Care Unit"],"prefix":"10.1007","volume":"22","author":[{"given":"Alok","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Starane A.","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,13]]},"reference":[{"issue":"5","key":"616_CR1","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1002\/(SICI)1097-4598(199805)21:5<610::AID-MUS7>3.0.CO;2-B","volume":"21","author":"D Lacomis","year":"1998","unstructured":"Lacomis D, Petrella JT, Giuliani MJ. Causes of neuromuscular weakness in the intensive care unit: a study of ninety-two patients. Muscle Nerve. 1998;21(5):610\u20137.","journal-title":"Muscle Nerve"},{"issue":"3","key":"616_CR2","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.anclin.2016.04.010","volume":"34","author":"V Crespo","year":"2016","unstructured":"Crespo V, James ML. Neuromuscular disease in the neurointensive care unit. Anesthesiol Clin. 2016;34(3):601\u201319.","journal-title":"Anesthesiol Clin"},{"issue":"2","key":"616_CR3","first-page":"85","volume":"13","author":"C Heatwole","year":"2011","unstructured":"Heatwole C. et al. Plasma Exchange versus Intravenous Immunoglobulin for Myasthenia Gravis Crisis: An Acute Hospital Cost Comparison Study. 2011;13(2):85\u201394.","journal-title":"Plasma Exchange versus Intravenous Immunoglobulin for Myasthenia Gravis Crisis: An Acute Hospital Cost Comparison Study"},{"issue":"3","key":"616_CR4","first-page":"127","volume":"12","author":"JT Guptill","year":"2019","unstructured":"Guptill JT, Runken MC, Eaddy M, Lunacsek O, Fuldeore RM. Treatment patterns and costs of chronic inflammatory demyelinating polyneuropathy: a claims database analysis. Am Health Drug Benefits. 2019;12(3):127\u201335.","journal-title":"Am Health Drug Benefits"},{"issue":"3","key":"616_CR5","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.pbj.2017.02.002","volume":"2","author":"J Peres","year":"2017","unstructured":"Peres J, et al. Rituximab in generalized myasthenia gravis: clinical, quality of life and cost\u2013utility analysis. Porto Biomedical Journal. 2017;2(3):81\u20135.","journal-title":"Porto Biomedical Journal"},{"issue":"9","key":"616_CR6","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1007\/s004150050141","volume":"244","author":"DM Bonifati","year":"1997","unstructured":"Bonifati DM, Angelini C. Long-term cyclosporine treatment in a group of severe myasthenia gravis patients. J Neurol. 1997;244(9):542\u20137.80.","journal-title":"J Neurol"},{"key":"616_CR7","unstructured":"Stone K. The most expensive prescription drugs in the world 2018 [updated 12\/30\/2018]. Available from: https:\/\/www.thebalance.com\/the-8-most-expensive-prescription-drugs-in-the-world-2663232."},{"key":"616_CR8","unstructured":"Azathioprine: drug information: UpToDate Inc; Available from: https:\/\/www.uptodate.com\/contents\/azathioprine-drug-information?search=azathioprine&source=panel_search_result&selectedTitle=1~149&usage_type=panel&kp_tab=drug_general&display_rank=1#F138204."},{"key":"616_CR9","unstructured":"Cyclophosphamide: drug information: UpToDate Inc; Available from: https:\/\/www.uptodate.com\/contents\/cyclophosphamide-drug-information?sectionName=Adult&topicId=9308&search=cyclophosphamide%20drug%20information&usage_type=panel&anchor=F155460&source=panel_search_result&selectedTitle=1~148&kp_tab=drug_general&display_rank=1#F155437."},{"issue":"4","key":"616_CR10","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1097\/CND.0000000000000235","volume":"20","author":"AZ Burakgazi","year":"2019","unstructured":"\u2022 Burakgazi AZ. Immunoglobulin treatment in neuromuscular medicine. J Clin Neuromuscul Dis. 2019;20(4):182\u201393 Provides details on IVIg therapy in NMD.","journal-title":"J Clin Neuromuscul Dis"},{"key":"616_CR11","doi-asserted-by":"crossref","unstructured":"\u2022 Osman C, et al. Plasma exchange in neurological disease. Pract Neurol. 2019:practneurol-201 Provides details on plasma exchange in NMD.","DOI":"10.1136\/practneurol-2019-002336"},{"issue":"1","key":"616_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.5603\/AIT.2013.0002","volume":"45","author":"W Szczeklik","year":"2013","unstructured":"Szczeklik W, Wawrzycka K, W\u0142udarczyk A, Sega A, Nowak I, Seczy\u0144ska B, et al. Complications in patients treated with plasmapheresis in the intensive care unit. Anaesthesiol Intensive Ther. 2013;45(1):7\u201313.","journal-title":"Anaesthesiol Intensive Ther"},{"issue":"6","key":"616_CR13","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/j.1600-0404.1998.tb05968.x","volume":"97","author":"C Lindberg","year":"1998","unstructured":"Lindberg C, Andersen O, Lefvert AK. Treatment of myasthenia gravis with methylprednisolone pulse: a double blind study. Acta Neurol Scand. 1998;97(6):370\u20133.","journal-title":"Acta Neurol Scand"},{"issue":"6","key":"616_CR14","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/ncpneuro0810","volume":"4","author":"S Sathasivam","year":"2008","unstructured":"Sathasivam S. Steroids and immunosuppressant drugs in myasthenia gravis. Nat Clin Pract Neurol. 2008;4(6):317\u201327.","journal-title":"Nat Clin Pract Neurol"},{"issue":"772","key":"616_CR15","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1136\/pgmj.66.772.102","volume":"66","author":"V Fonseca","year":"1990","unstructured":"Fonseca V, Havard CW. Long term treatment of myasthenia gravis with azathioprine. Postgrad Med J. 1990;66(772):102\u20135.","journal-title":"Postgrad Med J"},{"key":"616_CR16","doi-asserted-by":"crossref","unstructured":"A randomised clinical trial comparing prednisone and azathioprine in myasthenia gravis. Results of the second interim analysis. Myasthenia Gravis Clinical Study Group. J Neurol Neurosurg Psychiatry. 1993;56(11):1157\u201363.","DOI":"10.1136\/jnnp.56.11.1157"},{"issue":"6","key":"616_CR17","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","volume":"50","author":"J Palace","year":"1998","unstructured":"Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology. 1998;50(6):1778\u201383.","journal-title":"Neurology"},{"issue":"1","key":"616_CR18","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1212\/WNL.31.1.32","volume":"31","author":"MC Perez","year":"1981","unstructured":"Perez MC, Buot WL, Mercado-Danguilan C, Bagabaldo ZG, Renales LD. Stable remissions in myasthenia gravis. Neurology. 1981;31(1):32\u20137.","journal-title":"Neurology"},{"issue":"1","key":"616_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/mus.10133","volume":"26","author":"LG De Feo","year":"2002","unstructured":"De Feo LG, et al. Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis. Muscle Nerve. 2002;26(1):31\u20136.","journal-title":"Muscle Nerve"},{"issue":"1","key":"616_CR20","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1196\/annals.1405.033","volume":"1132","author":"DB Drachman","year":"2008","unstructured":"Drachman DB, et al. Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis. Ann N Y Acad Sci. 2008;1132(1):305\u201314.","journal-title":"Ann N Y Acad Sci"},{"issue":"Suppl 2","key":"616_CR21","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1097\/00001813-200211002-00002","volume":"13","author":"T Cerny","year":"2002","unstructured":"Cerny T, et al. Mechanism of action of rituximab. Anti-Cancer Drugs. 2002;13(Suppl 2):S3\u201310.","journal-title":"Anti-Cancer Drugs"},{"issue":"2\u20133","key":"616_CR22","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S0162-3109(00)00192-2","volume":"47","author":"S Matsuda","year":"2000","unstructured":"Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology. 2000;47(2\u20133):119\u201325.","journal-title":"Immunopharmacology"},{"issue":"6","key":"616_CR23","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/00007691-199512000-00007","volume":"17","author":"AW Thomson","year":"1995","unstructured":"Thomson AW, Bonham CA, Zeevi A. Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit. 1995;17(6):584\u201391.","journal-title":"Ther Drug Monit"},{"issue":"3","key":"616_CR24","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1212\/WNL.55.3.448","volume":"55","author":"E Ciafaloni","year":"2000","unstructured":"Ciafaloni E, et al. Retrospective analysis of the use of cyclosporine in myasthenia gravis. Neurology. 2000;55(3):448\u201350.","journal-title":"Neurology"},{"key":"616_CR25","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1196\/annals.1405.000","volume":"1132","author":"JM Ponseti","year":"2008","unstructured":"Ponseti JM, Gamez J, Azem J, L\u00f3pez-Cano M, Vilallonga R, Armengol M. Tacrolimus for myasthenia gravis: a clinical study of 212 patients. Ann N Y Acad Sci. 2008;1132:254\u201363.","journal-title":"Ann N Y Acad Sci"},{"key":"616_CR26","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1471-2377-10-46","volume":"10","author":"AS Carr","year":"2010","unstructured":"Carr AS, et al. A systematic review of population based epidemiological studies in myasthenia gravis. BMC Neurol. 2010;10:46.","journal-title":"BMC Neurol"},{"key":"616_CR27","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/B978-0-444-63600-3.00013-1","volume":"140","author":"EF Wijdicks","year":"2017","unstructured":"\u2022 Wijdicks EF. Management of acute neuromuscular disorders. Handb Clin Neurol. 2017;140:229\u201337 Provides comprehensive summary of NMD management in ICU.","journal-title":"Handb Clin Neurol"},{"issue":"6, Muscle and N","key":"616_CR28","first-page":"1978","volume":"22","author":"MW Nicolle","year":"2016","unstructured":"Nicolle MW. Myasthenia gravis and Lambert-Eaton myasthenic syndrome. Continuum (Minneap Minn). 2016;22(6, Muscle and Neuromuscular Junction Disorders):1978\u20132005.","journal-title":"Continuum (Minneap Minn)"},{"issue":"1","key":"616_CR29","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/joa.12034","volume":"224","author":"I Koneczny","year":"2014","unstructured":"Koneczny I, Cossins J, Vincent A. The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis. J Anat. 2014;224(1):29\u201335.","journal-title":"J Anat"},{"issue":"4","key":"616_CR30","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s40265-019-1065-0","volume":"79","author":"G Beecher","year":"2019","unstructured":"\u2022\u2022 Beecher G, Putko BN, Wagner AN, Siddiqi ZA. Therapies directed against B-cells and downstream effectors in generalized autoimmune myasthenia gravis: current status. Drugs. 2019;79(4):353\u201364 Provides additional details on ritixumab and its mechanism for immunomodulation.","journal-title":"Drugs"},{"issue":"10","key":"616_CR31","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.autrev.2014.08.037","volume":"13","author":"S Berrih-Aknin","year":"2014","unstructured":"Berrih-Aknin S. Cortactin: a new target in autoimmune myositis and myasthenia gravis. Autoimmun Rev. 2014;13(10):1001\u20132.","journal-title":"Autoimmun Rev"},{"issue":"4","key":"616_CR32","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1007\/s00415-015-7963-5","volume":"263","author":"S Binks","year":"2016","unstructured":"Binks S, Vincent A, Palace J. Myasthenia gravis: a clinical-immunological update. J Neurol. 2016;263(4):826\u201334.","journal-title":"J Neurol"},{"issue":"3","key":"616_CR33","doi-asserted-by":"publisher","first-page":"e91816","DOI":"10.1371\/journal.pone.0091816","volume":"9","author":"B Zhang","year":"2014","unstructured":"Zhang B, Shen C, Bealmear B, Ragheb S, Xiong WC, Lewis RA, et al. Autoantibodies to Agrin in myasthenia gravis patients. PLoS One. 2014;9(3):e91816.","journal-title":"PLoS One"},{"issue":"5","key":"616_CR34","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1212\/WNL.48.5.1253","volume":"48","author":"CE Thomas","year":"1997","unstructured":"Thomas CE, Mayer SA, Gungor Y, Swarup R, Webster EA, Chang I, et al. Myasthenic crisis: clinical features, mortality, complications, and risk factors for prolonged intubation. Neurology. 1997;48(5):1253\u201360.","journal-title":"Neurology"},{"key":"616_CR35","first-page":"Cd002277","volume":"12","author":"P Gajdos","year":"2012","unstructured":"Gajdos P, Chevret S, Toyka KV. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev. 2012;12:Cd002277.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"616_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1749-6632.2012.06767.x","volume":"1275","author":"V Bril","year":"2012","unstructured":"Bril V, et al. IVIG and PLEX in the treatment of myasthenia gravis. Ann N Y Acad Sci. 2012;1275(1):1\u20136.","journal-title":"Ann N Y Acad Sci"},{"issue":"5","key":"616_CR37","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/NRL.0000000000000026","volume":"19","author":"PS Dhawan","year":"2015","unstructured":"Dhawan PS, Goodman BP, Harper CM, Bosch PE, Hoffman-Snyder CR, Wellik KE, et al. IVIG versus PLEX in the treatment of worsening myasthenia gravis: what is the evidence?: a critically appraised topic. Neurologist. 2015;19(5):145\u20138.","journal-title":"Neurologist"},{"issue":"7","key":"616_CR38","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/j.1468-1331.2010.03019.x","volume":"17","author":"GO Skeie","year":"2010","unstructured":"Skeie GO, Apostolski S, Evoli A, Gilhus NE, Illa I, Harms L, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol. 2010;17(7):893\u2013902.","journal-title":"Eur J Neurol"},{"issue":"3","key":"616_CR39","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s40265-018-0875-9","volume":"78","author":"S Dhillon","year":"2018","unstructured":"Dhillon S. Eculizumab: a review in generalized myasthenia gravis. Drugs. 2018;78(3):367\u201376.","journal-title":"Drugs"},{"issue":"12","key":"616_CR40","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard Jr","year":"2017","unstructured":"\u2022\u2022 Howard JF Jr, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16(12):976\u201386 Landmark trial which resulted in approval of eculizumab in treatment of MG.","journal-title":"Lancet Neurol"},{"key":"616_CR41","doi-asserted-by":"crossref","unstructured":"Edmundson C, Guidon AC. Eculizumab: a complementary addition to existing long-term therapies for myasthenia gravis. Muscle Nerve. 2019.","DOI":"10.1002\/mus.26512"},{"issue":"23","key":"616_CR42","doi-asserted-by":"publisher","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","volume":"92","author":"JF Howard","year":"2019","unstructured":"\u2022\u2022 Howard JF, et al. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology. 2019;92(23):e2661\u201373 Landmark phase 2 study which showed safety and efficacy of using efgartigimod in MG.","journal-title":"Neurology"},{"issue":"24","key":"616_CR43","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1056\/NEJMra1114525","volume":"366","author":"N Yuki","year":"2012","unstructured":"Yuki N, Hartung H-P. Guillain\u2013Barr\u00e9 syndrome. N Engl J Med. 2012;366(24):2294\u2013304.","journal-title":"N Engl J Med"},{"issue":"2","key":"616_CR44","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1159\/000184748","volume":"32","author":"A McGrogan","year":"2009","unstructured":"McGrogan A, Madle GC, Seaman HE, de Vries CS. The epidemiology of Guillain-Barr\u00e9 syndrome worldwide. Neuroepidemiology. 2009;32(2):150\u201363.","journal-title":"Neuroepidemiology"},{"issue":"2","key":"616_CR45","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000324710","volume":"36","author":"JJ Sejvar","year":"2011","unstructured":"Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barr\u00e9 syndrome: a systematic review and meta-analysis. Neuroepidemiology. 2011;36(2):123\u201333.","journal-title":"Neuroepidemiology"},{"key":"616_CR46","doi-asserted-by":"crossref","unstructured":"Wu X, et al. Predictors for mechanical ventilation and short-term prognosis in patients with Guillain-Barr\u00e9 syndrome. Crit Care. 2015;19(1).","DOI":"10.1186\/s13054-015-1037-z"},{"issue":"2","key":"616_CR47","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1177\/1941875210396379","volume":"1","author":"M Harms","year":"2011","unstructured":"Harms M. Inpatient management of Guillain-Barr\u00e9 syndrome. Neurohospitalist. 2011;1(2):78\u201384.","journal-title":"Neurohospitalist"},{"key":"616_CR48","doi-asserted-by":"crossref","unstructured":"Hughes RAC, et al. Corticosteroids for Guillain-Barr\u00e9 syndrome. Cochrane Database Syst Rev. 2016;10.","DOI":"10.1002\/14651858.CD001446.pub5"},{"key":"616_CR49","doi-asserted-by":"crossref","unstructured":"Lawn ND, et al. Anticipating mechanical ventilation in Guillain-Barr\u00e9 syndrome. 2001;58(6):893.","DOI":"10.1001\/archneur.58.6.893"},{"issue":"2","key":"616_CR50","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jcrc.2013.10.026","volume":"29","author":"MA Kannan Kanikannan","year":"2014","unstructured":"Kannan Kanikannan MA, Durga P, Venigalla NK, Kandadai RM, Jabeen SA, Borgohain R. Simple bedside predictors of mechanical ventilation in patients with Guillain-Barre syndrome. J Crit Care. 2014;29(2):219\u201323.","journal-title":"J Crit Care"},{"issue":"9","key":"616_CR51","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.it.2013.05.001","volume":"34","author":"HJ Willison","year":"2013","unstructured":"Willison HJ, Goodyear CS. Glycolipid antigens and autoantibodies in autoimmune neuropathies. Trends Immunol. 2013;34(9):453\u20139.","journal-title":"Trends Immunol"},{"key":"616_CR52","doi-asserted-by":"crossref","unstructured":"\u2022 Chevret S, Hughes RAC, Annane D. Plasma exchange for Guillain-Barr\u00e9 syndrome. Cochrane Database Syst Rev. 2017;(2) Provides an overall summary of several previously published articles on use of PLEX in treatment of GBS.","DOI":"10.1002\/14651858.CD001798.pub3"},{"issue":"6","key":"616_CR53","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1474-4422(18)30114-5","volume":"17","author":"S Misawa","year":"2018","unstructured":"\u2022\u2022 Misawa S, et al. Safety and efficacy of eculizumab in Guillain-Barr\u00e9 syndrome: a multicentre, double-blind, randomised phase 2 trial. Lancet Neurol. 2018;17(6):519\u201329 Phase 2 trial which showed safety of eculizumab in GBS. Efficacy not established from small study, albeit there was an overall trend towards improvement.","journal-title":"Lancet Neurol"},{"issue":"1","key":"616_CR54","first-page":"57","volume":"46","author":"B Marin","year":"2017","unstructured":"Marin B, Boum\u00e9diene F, Logroscino G, Couratier P, Babron MC, Leutenegger AL, et al. Variation in worldwide incidence of amyotrophic lateral sclerosis: a meta-analysis. Int J Epidemiol. 2017;46(1):57\u201374.","journal-title":"Int J Epidemiol"},{"issue":"7","key":"616_CR55","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s10654-018-0392-x","volume":"33","author":"B Marin","year":"2018","unstructured":"Marin B, Fontana A, Arcuti S, Copetti M, Boum\u00e9diene F, Couratier P, et al. Age-specific ALS incidence: a dose-response meta-analysis. Eur J Epidemiol. 2018;33(7):621\u201334.","journal-title":"Eur J Epidemiol"},{"issue":"2","key":"616_CR56","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1056\/NEJMra1603471","volume":"377","author":"RH Brown","year":"2017","unstructured":"Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377(2):162\u201372.","journal-title":"N Engl J Med"},{"key":"616_CR57","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.envint.2016.02.014","volume":"91","author":"JD Beard","year":"2016","unstructured":"Beard JD, Engel LS, Richardson DB, Gammon MD, Baird C, Umbach DM, et al. Military service, deployments, and exposures in relation to amyotrophic lateral sclerosis etiology. Environ Int. 2016;91:104\u201315.","journal-title":"Environ Int"},{"key":"616_CR58","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3389\/fncel.2017.00080","volume":"11","author":"R Bonafede","year":"2017","unstructured":"Bonafede R, Mariotti R. ALS pathogenesis and therapeutic approaches: the role of mesenchymal stem cells and extracellular vesicles. Front Cell Neurosci. 2017;11:80.","journal-title":"Front Cell Neurosci"},{"issue":"9013","key":"616_CR59","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/S0140-6736(96)91680-3","volume":"347","author":"GB Lucette Lacomblez","year":"1996","unstructured":"Lucette Lacomblez GB, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis\/Riluzole Study Group II. Lancet. 1996;347(9013):1425\u201331.","journal-title":"Lancet"},{"issue":"7","key":"616_CR60","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S1474-4422(17)30115-1","volume":"16","author":"K Abe","year":"2017","unstructured":"\u2022 Abe K, et al. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(7):505\u201312 Randomized trial which showed safety and efficacy of Edaravone in ALS.","journal-title":"Lancet Neurol"},{"issue":"7\u20138","key":"616_CR61","doi-asserted-by":"publisher","first-page":"610","DOI":"10.3109\/21678421.2014.959024","volume":"15","author":"K Abe","year":"2014","unstructured":"Abe K, et al. Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(7\u20138):610\u20137.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"616_CR62","unstructured":"Available from: https:\/\/www.radicava.com\/assets\/dist\/pdfs\/radicava-prescribing-information.pdf."},{"key":"616_CR63","doi-asserted-by":"publisher","first-page":"486","DOI":"10.3389\/fneur.2017.00486","volume":"8","author":"SI Khalid","year":"2017","unstructured":"Khalid SI, et al. Immune modulation in the treatment of amyotrophic lateral sclerosis: a review of clinical trials. Front Neurol. 2017;8:486.","journal-title":"Front Neurol"},{"issue":"3","key":"616_CR64","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1128\/CMR.00001-08","volume":"21","author":"NF Crum-Cianflone","year":"2008","unstructured":"Crum-Cianflone NF. Bacterial, fungal, parasitic, and viral myositis. Clin Microbiol Rev. 2008;21(3):473\u201394.","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"616_CR65","first-page":"126","volume":"18","author":"J Robinson-Papp","year":"2012","unstructured":"Robinson-Papp J. Infectious neuropathies. CONTINUUM: Lifelong Learning in Neurology. 2012;18(1):126\u201338.","journal-title":"CONTINUUM: Lifelong Learning in Neurology"},{"issue":"8","key":"616_CR66","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.3201\/eid1108.050289a","volume":"11","author":"EB Hayes","year":"2005","unstructured":"Hayes EB, Komar N, Nasci RS, Montgomery SP, O\u2019Leary DR, Campbell GL. Epidemiology and transmission dynamics of West Nile virus disease. Emerg Infect Dis. 2005;11(8):1167\u201373.","journal-title":"Emerg Infect Dis"},{"issue":"8","key":"616_CR67","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.3201\/eid1108.050289b","volume":"11","author":"EB Hayes","year":"2005","unstructured":"Hayes EB, Sejvar JJ, Zaki SR, Lanciotti RS, Bode AV, Campbell GL. Virology, pathology, and clinical manifestations of West Nile virus disease. Emerg Infect Dis. 2005;11(8):1174\u20139.","journal-title":"Emerg Infect Dis"},{"issue":"12","key":"616_CR68","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1086\/518281","volume":"44","author":"JM Hughes","year":"2007","unstructured":"Hughes JM, Wilson ME, Sejvar JJ. The long-term outcomes of human West Nile virus infection. Clin Infect Dis. 2007;44(12):1617\u201324.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"616_CR69","doi-asserted-by":"publisher","first-page":"811","DOI":"10.3390\/v3060811","volume":"3","author":"SM Lim","year":"2011","unstructured":"Lim SM, Koraka P, Osterhaus AD, Martina BE. West Nile virus: immunity and pathogenesis. Viruses. 2011;3(6):811\u201328.","journal-title":"Viruses"},{"issue":"14 Supplement","key":"616_CR70","doi-asserted-by":"crossref","first-page":"P5.114","DOI":"10.1212\/WNL.84.14_supplement.P5.114","volume":"84","author":"R Fateh","year":"2015","unstructured":"Fateh R, et al. Interferon-alpha in a patient with West Nile virus myelitis: a case-report. (P5.114). Neurology. 2015;84(14 Supplement):P5.114.","journal-title":"Neurology"},{"key":"616_CR71","doi-asserted-by":"crossref","unstructured":"Shimoni Z, et al. The clinical response of West Nile virus neuroinvasive disease to intravenous immunoglobulin therapy. Clin Pract. 2012;2(1):e18\u20138.","DOI":"10.4081\/cp.2012.e18"},{"issue":"1","key":"616_CR72","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/1471-2334-14-248","volume":"14","author":"J Hart","year":"2014","unstructured":"Hart J, et al. West Nile virus neuroinvasive disease: neurological manifestations and prospective longitudinal outcomes. BMC Infect Dis. 2014;14(1):248.","journal-title":"BMC Infect Dis"},{"key":"616_CR73","unstructured":"National Botulism Surveillance Center of Disease Control and Prevention [updated June 6, 2019. Available from: https:\/\/www.cdc.gov\/botulism\/surveillance.html."},{"issue":"1","key":"616_CR74","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1159\/000083259","volume":"53","author":"D Dressler","year":"2005","unstructured":"Dressler D, Adib SF. Botulinum toxin: mechanisms of action. Eur Neurol. 2005;53(1):3\u20139.","journal-title":"Eur Neurol"},{"key":"616_CR75","unstructured":"Botulism in United States, 1899\u20131996. Handbook for epidemiologists, clinicians, and laboratory workers Center of Disease Control and Prevention; 1998."},{"issue":"1","key":"616_CR76","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1146\/annurev.pharmtox.44.101802.121554","volume":"44","author":"LL Simpson","year":"2004","unstructured":"Simpson LL. Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol. 2004;44(1):167\u201393.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"616_CR77","doi-asserted-by":"crossref","unstructured":"Robinson RF, Nahata MC. Management of botulism. 2003;37:127\u201331.","DOI":"10.1345\/aph.1C034"}],"container-title":["Current Treatment Options in Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-020-0616-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11940-020-0616-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11940-020-0616-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T15:06:22Z","timestamp":1722438382000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11940-020-0616-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,13]]},"references-count":77,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["616"],"URL":"https:\/\/doi.org\/10.1007\/s11940-020-0616-8","relation":{},"ISSN":["1092-8480","1534-3138"],"issn-type":[{"value":"1092-8480","type":"print"},{"value":"1534-3138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,13]]},"assertion":[{"value":"13 February 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Patel declares that he has no conflict of interest.Dr. Lynch declares that she has no conflict of interest.Dr. Shepherd declares that he has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"7"}}